CD63 and central nervous system cancer: In a 2018 study led by Qiu et al., an innovative biosensor named BAF-TiN was introduced as a precise and efficient tool for quantifying glioma-derived exosomes, with a specific focus on the CD63 marker and the glioma-associated protein EGFRvIII, which plays a pivotal role in glioma diagnosis.